Abstract |
The aim of the present study is to evaluate the clinical and biological factors (including markers of angiogenesis) as potential predictors of prognosis and benefit from metronomic therapy in patients with advanced breast cancer (ABC). Recent data suggest antiangiogenic activity of metronomic therapy. The study population included 62 patients with pretreated ABC who received cyclophosphamide and methotrexate orally. Tumour samples were analysed by immunohistochemistry for HER2, Ki-67, thymidine phosphorylase (TP), vascular endothelial growth factor and vascular endothelial growth factor receptor. The results from immunohistochemical analysis and clinico-pathological variables were studied to test their potential association with benefit from metronomic therapy. The median overall survival, progression-free survival and survival postprogression were 7.1 (range 0.2-38.3), 2.6 (range 0.2-28.9) and 3 (range 0-34.2) months, respectively. Among the clinical variables, age, performance status and previous therapy with taxanes were significantly associated with outcomes. Among the molecular markers, TP was found to be associated with progression-free survival. Metronomic therapy is an effective choice for ABC. Young women with a more indolent disease had the greatest benefit from this treatment. TP tumour expression might aid decision making but these findings must be confirmed in larger prospective, properly designed studies.
|
Authors | Manuela Miscoria, Fabrizio Tonetto, Laura Deroma, Piernicola Machin, Carla Di Loreto, Pamela Driol, Alessandro Marco Minisini, Stefania Russo, Claudia Andreetta, Mauro Mansutti, Giuseppe Damante, Gianpiero Fasola, Fabio Puglisi |
Journal | Anti-cancer drugs
(Anticancer Drugs)
Vol. 23
Issue 3
Pg. 326-34
(Mar 2012)
ISSN: 1473-5741 [Electronic] England |
PMID | 22129512
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Ki-67 Antigen
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Cyclophosphamide
- Thymidine Phosphorylase
- ERBB2 protein, human
- Receptor, ErbB-2
- Receptors, Vascular Endothelial Growth Factor
- Methotrexate
|
Topics |
- Administration, Metronomic
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Breast Neoplasms
(drug therapy, metabolism, mortality, pathology)
- Cyclophosphamide
(administration & dosage, therapeutic use)
- Disease-Free Survival
- Female
- Humans
- Ki-67 Antigen
(metabolism)
- Methotrexate
(administration & dosage, therapeutic use)
- Middle Aged
- Multivariate Analysis
- Predictive Value of Tests
- Prognosis
- Receptor, ErbB-2
(metabolism)
- Receptors, Vascular Endothelial Growth Factor
(metabolism)
- Thymidine Phosphorylase
(metabolism)
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(metabolism)
|